Table 5 Corticosteroid therapy among patients with severe COVID-19 and HBV co-infection
Characteristics | All patients N = 55 | Survivor N = 39 | Non-survivor N = 16 | P value |
|---|---|---|---|---|
Time from symptom onset to corticosteroid initiation, median (IQR), days | 15 (10, 19) | 15 (10, 25) | 14 (9, 17) | 0.500 |
 < 7 days, n (%) | 7 (12.7) | 6 (15.4) | 1 (6.3) | 0.633 |
 ≥ 7 days, n (%) | 48 (87.3) | 33 (84.6) | 15 (93.8) |  |
Time from ARDS onset to corticosteroid initiation, median (IQR), days | 0 (− 1, 1) | 0 (− 1, 0) | 0 (− 2, 5) | 0.324 |
 < 3 days, n (%) | 28 (50.9) | 19 (48.7) | 9 (56.3) | 0.612 |
 ≥ 3 days, n (%) | 27 (49.1) | 20 (51.3) | 7 (43.8) |  |
Duration of corticosteroid, median (IQR), days | 5 (1, 7) | 5 (1, 7) | 6 (2, 10) | 0.396 |
 < 7 days, n (%) | 42 (76.4) | 32 (82.1) | 10 (62.5) | 0.121 |
 ≥ 7 days, n (%) | 13 (23.6) | 7 (17.9) | 6 (37.5) |  |
Cumulative dosage during the whole course of treatment | 248(105,460) | 200 (102, 280) | 430 (236, 1094) | 0.014 |
 < 400 mg, n (%) | 41 (74.5) | 33 (84.6) | 8 (50.0) | 0.007 |
 ≥ 400 mg, n (%) | 14 (25.5) | 6 (15.4) | 8 (50.0) |  |
Dose per day (mg) | 40 (40, 80) | 40 (40,46) | 83 (50, 106) | 0.113 |
 < 80 | 42 (76.4) | 34 (87.2) | 8 (50.0) | 0.003 |
 ≥ 80 | 13 (23.6) | 5 (12.8) | 8 (50.0) |  |
Time from symptom onset to discharge or death, median (IQR), days | 24 (19, 33) | 24 (19, 36) | 22 (18,27) | 0.133 |
Time from corticosteroid initiation to discharge or death, median (IQR), days | 14 (6, 21) | 14 (7, 23) | 11 (4, 19) | 0.453 |